Next Article in Journal
Sonic Hedgehog Medulloblastoma Cancer Stem Cells Mirnome and Transcriptome Highlight Novel Functional Networks
Next Article in Special Issue
Biological Aspects of mTOR in Leukemia
Previous Article in Journal
Non-Ionizing Radiation for Cardiac Human Amniotic Mesenchymal Stromal Cell Commitment: A Physical Strategy in Regenerative Medicine
Previous Article in Special Issue
mTOR and Tumor Cachexia
Open AccessReview

mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases

Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(8), 2325; https://doi.org/10.3390/ijms19082325
Received: 4 June 2018 / Revised: 22 July 2018 / Accepted: 30 July 2018 / Published: 8 August 2018
(This article belongs to the Special Issue mTOR in Human Diseases)
Chronological age represents the greatest risk factor for many life-threatening diseases, including neurodegeneration, cancer, and cardiovascular disease; ageing also increases susceptibility to infectious disease. Current efforts to tackle individual diseases may have little impact on the overall healthspan of older individuals, who would still be vulnerable to other age-related pathologies. However, recent progress in ageing research has highlighted the accumulation of senescent cells with chronological age as a probable underlying cause of pathological ageing. Cellular senescence is an essentially irreversible proliferation arrest mechanism that has important roles in development, wound healing, and preventing cancer, but it may limit tissue function and cause widespread inflammation with age. The serine/threonine kinase mTOR (mechanistic target of rapamycin) is a regulatory nexus that is heavily implicated in both ageing and senescence. Excitingly, a growing body of research has highlighted rapamycin and other mTOR inhibitors as promising treatments for a broad spectrum of age-related pathologies, including neurodegeneration, cancer, immunosenescence, osteoporosis, rheumatoid arthritis, age-related blindness, diabetic nephropathy, muscular dystrophy, and cardiovascular disease. In this review, we assess the use of mTOR inhibitors to treat age-related pathologies, discuss possible molecular mechanisms of action where evidence is available, and consider strategies to minimize undesirable side effects. We also emphasize the urgent need for reliable, non-invasive biomarkers of senescence and biological ageing to better monitor the efficacy of any healthy ageing therapy. View Full-Text
Keywords: mTOR; mTORC1; mTORC2; rapamycin; rapalogues; rapalogs; mTOR inhibitors; senescence; ageing; aging; cancer; neurodegeneration; immunosenescence; senolytics; biomarkers mTOR; mTORC1; mTORC2; rapamycin; rapalogues; rapalogs; mTOR inhibitors; senescence; ageing; aging; cancer; neurodegeneration; immunosenescence; senolytics; biomarkers
Show Figures

Figure 1

MDPI and ACS Style

Walters, H.E.; Cox, L.S. mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases. Int. J. Mol. Sci. 2018, 19, 2325.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop